Matthew Shawn Morris Sells 16,550 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 16,550 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $25.00, for a total transaction of $413,750.00. Following the completion of the transaction, the director directly owned 68,188 shares in the company, valued at approximately $1,704,700. This represents a 19.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Matthew Shawn Morris also recently made the following trade(s):

• On Thursday, February 26th, Matthew Shawn Morris sold 7,788 shares of Privia Health Group stock. The shares were sold at an average price of $24.99, for a total transaction of $194,622.12.
• On Friday, December 12th, Matthew Shawn Morris sold 13,647 shares of Privia Health Group stock. The shares were sold at an average price of $25.01, for a total value of $341,311.47.

Privia Health Group Stock Performance

NASDAQ:PRVA opened at $23.77 on Wednesday. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51. The stock has a market cap of $2.94 billion, a PE ratio of 139.82, a P/E/G ratio of 1.61 and a beta of 0.82. The stock has a 50 day moving average price of $23.07 and a 200 day moving average price of $23.54.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The company had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same period in the prior year, the business earned $0.21 EPS. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. As a group, analysts predict that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PRVA has been the topic of several recent analyst reports. Barclays increased their price target on shares of Privia Health Group from $22.00 to $23.00 and gave the company an “equal weight” rating in a research note on Monday, November 10th. Jefferies Financial Group reiterated a “buy” rating and issued a $32.00 price objective on shares of Privia Health Group in a report on Thursday, February 26th. Evercore raised their target price on Privia Health Group from $28.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Stephens restated an “overweight” rating and issued a $32.00 target price on shares of Privia Health Group in a research report on Thursday, December 4th. Finally, Royal Bank Of Canada started coverage on Privia Health Group in a report on Friday, January 9th. They set an “outperform” rating and a $31.00 price target for the company. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Privia Health Group has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Key Headlines Impacting Privia Health Group

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Q4 results beat expectations — PRVA reported $0.25 EPS vs. $0.04 expected and revenue of $541.2M (up 17.4% YoY), a clear near‑term fundamental positive that supports higher valuations. Read More.
• Positive Sentiment: Truist raised its price target from $31 to $33 and kept a “buy” rating, which signals institutional confidence and can attract buyers. Read More.
• Positive Sentiment: Privia agreed to acquire Evolent’s ACO business to scale value‑based care — a strategic deal that could expand managed‑care revenue and improve margins if integration succeeds. Read More.
• Positive Sentiment: Privia‑led colorectal cancer screening program achieved an 84% screening rate, demonstrating execution in preventive care and EHR‑driven workflows — useful evidence for payor and provider partnerships. Read More.
• Neutral Sentiment: Citigroup trimmed its price target from $34 to $32 but maintained a “buy” rating — slightly dampening upside expectations while leaving the investment thesis intact. Read More.
• Negative Sentiment: Director Matthew Shawn Morris sold ~24,338 shares across Feb. 26–27 (~$608k), reducing his stake materially; heavy director sales can create short‑term selling pressure and hurt sentiment. Read More.
• Negative Sentiment: CFO David Mountcastle sold ~13,058 shares across Feb. 26–27 (~$327k); insider sales by senior finance executives are closely watched and may temper enthusiasm despite other positives. Read More.

Institutional Trading of Privia Health Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Privia Health Group by 5.3% during the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after buying an additional 607,447 shares during the period. Durable Capital Partners LP raised its holdings in shares of Privia Health Group by 1.8% in the 3rd quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock valued at $291,123,000 after buying an additional 203,842 shares during the period. State Street Corp lifted its stake in Privia Health Group by 1.5% during the 2nd quarter. State Street Corp now owns 4,171,069 shares of the company’s stock worth $95,935,000 after acquiring an additional 61,853 shares in the last quarter. Van Berkom & Associates Inc. boosted its holdings in Privia Health Group by 1.8% during the 4th quarter. Van Berkom & Associates Inc. now owns 3,844,256 shares of the company’s stock valued at $91,147,000 after acquiring an additional 69,691 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Privia Health Group by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company’s stock valued at $66,738,000 after acquiring an additional 31,204 shares during the period. Hedge funds and other institutional investors own 94.48% of the company’s stock.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.